SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

SEC Comment Letter 0000000000-25-003358 to Valneva SE (VALN)

Valneva SE
Date: March 28, 2025 · CIK: 0001836564 · Accession: 0000000000-25-003358

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-286071

Date
March 28, 2025
Author
Division of
Form
UPLOAD
Company
Valneva SE

Letter

Re: Valneva SE Registration Statement on Form F-3 Filed March 25, 2025 File No. 333-286071 Dear Thomas Lingelbach:

March 28, 2025

Thomas Lingelbach Chief Executive Officer Valneva SE 6 rue Alain Bombard 44800 Saint-Herblain France

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Chris Edwards at 202-551-6761 with any questions.

Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Katie Kazem

Show Raw Text
<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
 March 28, 2025

Thomas Lingelbach
Chief Executive Officer
Valneva SE
6 rue Alain Bombard
44800 Saint-Herblain
France

 Re: Valneva SE
 Registration Statement on Form F-3
 Filed March 25, 2025
 File No. 333-286071
Dear Thomas Lingelbach:

 This is to advise you that we have not reviewed and will not review your
registration
statement.

 Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

 Please contact Chris Edwards at 202-551-6761 with any questions.

 Sincerely,

 Division of
Corporation Finance
 Office of Life
Sciences
cc: Katie Kazem
</TEXT>
</DOCUMENT>